Combination targeted therapy provides durable remission for patients with CLL

A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients …

Beyond remission: From alcohol dependence to optimal mental health

New research published online in the journal Substance Use & Misuse is good news for those struggling with alcohol dependence: the possibility of ending this dependency gets easier with age. Moreover, more than half of individuals who have been dependent on alcohol are free of any addictions or mental illness, and nearly 40% are in …